Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial

Phase 2positivePositive

AI Analysis

Summary

Cue Biopharma reported positive Phase 2 data for its chronic spontaneous urticaria candidate in a China study, representing its first clinical readout following a strategic shift from oncology to immunology.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Phase 2 China study in chronic spontaneous urticaria cleared

Importance:6/10

Sentiment:

0.80

immunologychronic hivesclinical trialstrategic pivot

Related Companies

$CHHE $TRAX

Read the original article

Published by Endpoints News on September 21, 2026 10:17 AM

Read Original